$OFIX

Juniper Investment Company, LLC (Bartholdson John A., MICHAS ALEXIS P) sold $403K of OFIX (indirect holdings)

Juniper Investment Company, LLC sold 39,500 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $10.20 ($10.01–$10.38, $0.40M total) across 2 trades over 2026-08-14 to 2026-08-17. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).

Original reporting
SEC EDGAR · Juniper Investment Company, LLC, Bartholdson John A., MICHAS ALEXIS P
Published Aug 18, 2026, 9:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$OFIX
Neutral
medium confidence
Mentioned
$OFIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale by a 10% owner (indirect holdings) totaling about $402.7K, with no pre-arranged 10b5-1 plan indicated.

02

Market read

Traders may monitor OFIX for sentiment effects from insider selling, but there is no new operational or financial guidance in the text.

03

What to watch

The filing does not state the owner’s rationale, and the transactions occurred over multiple days, reducing the signal of any single timing event.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-18, covering sales dated 2026-08-14 to 2026-08-17

Background

The article is a SEC Form 4 insider transaction disclosure for Orthofix Medical Inc. (OFIX).

Company-level read

Ticker impact

$OFIXNeutralMedium confidence
Context

Orthofix Medical Inc. disclosed a Form 4 showing a 10% owner sold 39,500 shares in open-market transactions at about $10.20.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than a new operating catalyst.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include earnings, guidance, litigation, or business changes. The sale size is moderate and the article provides no stated reason or plan details beyond 'no pre-arranged 10b5-1 plan.'

Market effects

Minimal sector read-through; this is company-specific insider selling with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

A 10% owner sale can be driven by diversification or liquidity needs and may not reflect negative fundamentals, especially without any accompanying negative company news.

Key entities

  • Orthofix Medical Inc.

    Subject of the Form 4 insider transaction disclosure (OFIX).

  • Juniper Investment Company, LLC

    Reporter of the Form 4, acting as a 10% owner with indirect holdings.

  • Bartholdson John A.

    Co-reporting 10% owner listed on the joint filing.

  • MICHAS ALEXIS P

    Co-reporting 10% owner listed on the joint filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OFIXMed

Orthofix Medical Inc. Q2 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q2 2026 earnings call updates, emphasizing a shift toward distributor quality and asset utilization. Management expects 2026 net sales and EBITDA guidance to rise by $7 million, citing $12 million Medicare reimbursement restoration and $15 million European distributor benefit, partly offset by weaker smaller spine distributors. Medicare bone stimulator reimbursement was restored retroactive to May 18, 2026.

$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

$OFIXMedAI 8/10

Why is Orthofix Medical stock surging today? By Investing.com

Orthofix Medical shares rose 15.3% after the company said CMS reversed earlier Medicare billing/fee-schedule changes for non-invasive bone growth stimulators, restoring reimbursement to prior levels. CMS issued revised guidance July 1, 2026, withdrawing modifications tied to HCPCS codes. The stock moved from near $8.85 toward $11.46; insiders sold about $2.7M over three months.